Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckKevin J. Harrington, Robert I. Haddad, Maura L. Gillison et al.|JAMA Oncology|2023Cited by 73
Prognostic value of the Hippo pathway transcriptional coactivators YAP/TAZ and β1-integrin in conventional osteosarcomaCorinne Bouvier, Sébastien Salas|Oncotarget|2016Cited by 55
Correlation between ERK1 and STAT3 expression and chemoresistance in patients with conventional osteosarcomaSébastien Salas, Corinne Bouvier|BMC Cancer|2014Cited by 29